Skip to Main Content

Author Details

Thomas Helleday
The University of Sheffield
1998
284
74
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37922465Targeting MTHFD2 to Exploit Cancer-Specific Metabolism and the DNA Damage Response.Cancer Res2024
37799492Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients.F1000Res2024
36128847Optimization of N-Piperidinyl-Benzimidazolone Derivatives as Potent and Selective Inhibitors of 8-Oxo-Guanine DNA Glycosylase 1.ChemMedChem2023
37978139Mitotic MTH1 Inhibitors in Treatment of Cancer.Cancer Treat Res2023
37084385Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.Blood2023
37012496Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells.Nat Metab2023
36880147Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy.Int J Immunopathol Pharmacol2023
36746968Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model.Nat Commun2023
36871087NUDT22 promotes cancer growth through pyrimidine salvage.Oncogene2023
36869333Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming.J Transl Med2023
34418425Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma.J Invest Dermatol2022
35737787Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function.Science2022
35583750Targeting the DNA damage response and repair in cancer through nucleotide metabolism.Mol Oncol2022
35732208Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir.J Biol Chem2022
35753523NUDT1 promotes the accumulation and longevity of CD103<sup>+</sup> T<sub>RM</sub> cells in primary biliary cholangitis.J Hepatol2022
35712863The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform-Selective Inhibitors.ChemMedChem2022
35619904OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.Front Oncol2022
36552885An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation.Cells2022
36551206Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer.Biomolecules2022
36037066Synthetic switches of OGG1 control initiation of base excision repair and offer new treatment strategies.Clin Transl Med2022
36324676Pharmacological OGG1 inhibition decreases murine allergic airway inflammation.Front Pharmacol2022
35948708Spatially resolved clonal copy number alterations in benign and malignant tissue.Nature2022
36115838Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.Nat Commun2022
36184897Precision oncology using ex vivo technology: a step towards individualised cancer care?Expert Rev Mol Med2022
35247918Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML.Mol Cancer Ther2022
35228749Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.Nat Cancer2022
34894107MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells.Hepatol Commun2022
34453118MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.Cell Death Differ2022
34192523NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir.Cell Chem Biol2021
33737576Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.Sci Rep2021
33568707Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects.Sci Rep2021
33676948MTH1 Inhibitors for the Treatment of Psoriasis.J Invest Dermatol2021
33925271NEIL1 and NEIL2 Are Recruited as Potential Backup for OGG1 upon OGG1 Depletion or Inhibition by TH5487.Int J Mol Sci2021
33753169Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity.J Biol Chem2021
35121938Polθ inhibitors unchained.Nat Cancer2021
34725125Editor's Note: Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer.Clin Cancer Res2021
34479993Defects in 8-oxo-guanine repair pathway cause high frequency of C &gt; A substitutions in neuroblastoma.Proc Natl Acad Sci U S A2021
34593524MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.Cancer Res2021
34045188NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis.Cancer Res2021
31285544The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity.Cell Death Differ2020
32029719Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.Cell Death Dis2020
32051232Cell Cycle Profiling Reveals Protein Oscillation, Phosphorylation, and Localization Dynamics.Mol Cell Proteomics2020
31959333Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles.Ann Oncol2020
32019870Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds.Cancer Res2020
31954130The First Structure of an Active Mammalian dCTPase and its Complexes With Substrate Analogs and Products.J Mol Biol2020
31919461AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.Cell Death Differ2020
32005748Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.Clin Cancer Res2020
33114607OGG1 Inhibitor TH5487 Alters OGG1 Chromatin Dynamics and Prevents Incisions.Biomolecules2020
33211885Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.Nucleic Acids Res2020
33322045Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses.Viruses2020
  • 1 - 50 of 284

Recommended Authors

Parasvi S Patel
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2016
Number of shared co-authors 1
Marc Wiedner
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Career Start Year 2013
Number of shared co-authors 4
David Gallo
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Career Start Year 2010
Number of shared co-authors 1
Srikanth Talluri
VA Boston Healthcare System
Career Start Year 2008
Number of shared co-authors 0
Jianfeng Li
Mitchell Cancer Institute, University of South Alabama
Career Start Year 2008
Number of shared co-authors 1
Georgia Velimezi
University of Patras
Career Start Year 2008
Number of shared co-authors 3
Abdelghani Mazouzi
Netherlands Cancer Institute
Career Start Year 2005
Number of shared co-authors 4
Serah Choi
University Hospitals Cleveland Medical Center and Case Comprehensive Cancer Center
Career Start Year 2004
Number of shared co-authors 0
Vikram Bhattacharjee
Fox Chase Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Kyle M Miller
The University of Texas at Austin
Career Start Year 2001
Number of shared co-authors 3
Junjie Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 1
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 1
Vera Gorbunova
University of Rochester
Career Start Year 1997
Number of shared co-authors 1
Agata Smogorzewska
Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12)
Career Start Year 1997
Number of shared co-authors 1
Ranjit S Bindra
Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 3
Simon J Boulton
The Francis Crick Institute
Career Start Year 1996
Number of shared co-authors 7
Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 2
Daniel Durocher
The Lunenfeld-Tannenbaum Research Institute, Mount Sinai Hospital
Career Start Year 1995
Number of shared co-authors 10
Christopher J Bakkenist
UPMC Hillman Cancer Center, University of Pittsburgh
Career Start Year 1994
Number of shared co-authors 1
Peter J McHugh
MRC Weatherall Institute of Molecular Medicine, University of Oxford
Career Start Year 1993
Number of shared co-authors 4
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 1
John W Phillips
University of California los angeles
Career Start Year 1988
Number of shared co-authors 0
Robert W Sobol
University of South Alabama
Career Start Year 1987
Number of shared co-authors 2
Feyruz V Rassool
University of Maryland Greenebaum Comprehensive Cancer Center
Career Start Year 1984
Number of shared co-authors 0
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 10
Bennett Van Houten
UPMC-Hillman Cancer Center, University of Pittsburgh
Career Start Year 1982
Number of shared co-authors 2
Ashok R Venkitaraman
University of Cambridge, Hutchison Research Centre
Career Start Year 1982
Number of shared co-authors 6
Stephen J Elledge
Howard Hughes Medical Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1982
Number of shared co-authors 3
Yves Pommier
Center for Cancer Research, National Cancer Institute
Career Start Year 1980
Number of shared co-authors 6
Alan D D'Andrea
Dana-Farber Cancer Institute
Career Start Year 1978
Number of shared co-authors 8

Collaborators

Ann-Sofie Jemth
Karolinska Institutet
Co-authored papers 45
Olga Loseva
Karolinska Institutet
Co-authored papers 33
P??l Stenmark
Stockholm University
Co-authored papers 32
Jos?? Manuel Calder??n-Monta??o
Faculty of Pharmacy, University of Seville
Co-authored papers 14
Jordi Carreras Puigvert
Department of Pharmaceutical Biosciences, Uppsala University
Co-authored papers 9
Megan Carter
Stockholm University
Co-authored papers 8
Per Artursson
Department of Pharmacy, Uppsala University
Co-authored papers 8
Mikael Altun
Karolinska Institutet
Co-authored papers 8
Maria H??ggblad
Karolinska Institute
Co-authored papers 8
Natalia Issaeva
The University of North Carolina at Chapel Hill
Co-authored papers 7
Erik L L Sonnhammer
Stockholm University
Co-authored papers 7
Ulf Martens
Stockholm University
Co-authored papers 6
Bo Lundgren
Stockholm University
Co-authored papers 6
Robert G Bristow
University of Toronto
Co-authored papers 5
Nina Gustafsson
Karolinska Institutet
Co-authored papers 5
Judith E Unterlass
Karolinska Institute
Co-authored papers 5
Freddie C Hamdy
University of Oxford
Co-authored papers 5
Johan Bostr??m
Karolinska Institutet
Co-authored papers 4
Janne Lehti??
Karolinska Institutet
Co-authored papers 4
Joakim Lundeberg
KTH Royal Institute of Technology
Co-authored papers 3
Stefan Knapp
Institute of Pharmaceutical Chemistry, Goethe University
Co-authored papers 3
Lars Egevad
Karolinska Institute
Co-authored papers 3
Ana Osorio
Familial Cancer Clinical Unit, Spanish National Cancer Research Centre
Co-authored papers 3
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 3
Ruqi Tang
Co-authored papers 2
Per-Henrik Edqvist
Uppsala University
Co-authored papers 2
Jennifer R Grandis
University of California san francisco
Co-authored papers 2
Mark S Lowenthal
Co-authored papers 2
Ronnie P-A Berntsson
Umea University
Co-authored papers 2
Ian G Mills
Queen's University Belfast
Co-authored papers 2
Release 1.2